RESOURCES

PEOPLE

Mark Boguski has been named senior vice president of R&D at Rosetta Inpharmatics (Kirkland, WA). Dr. Boguski is one of the founding members of the US National Center for Biotechnology Information



(NCBI) and an adjunct professor in the department of molecular biology and genetics at the Johns Hopkins University School of Medicine.

Julia R. Brown and Daniel M. Bradbury have been appointed executive vice presidents at Amylin Pharmaceuticals (San Diego, CA). Ms. Brown joins Amylin from Dura Pharmaceuticals, where she held the same position. Mr. Bradbury was promoted from his most recent position as senior vice president of corporate development at Amylin.

Thomas O. Daniel is the new vice president of vascular biology, discovery research, at Immunex (Seattle, WA). Dr. Daniel was most recently director of the Vanderbilt University Center for Vascular Biology and professor of medicine and cell biology.

Gene Logic (Gaithersburg, MD) has named Mark D. Gessler to succeed Michael J. Brennan as CEO. Mr. Gessler joined the company in June 1996, and has served as president and COO since January 1999. Dr. Brennan, who founded Gene Logic and had been its only CEO, will continue to serve as chairman of the board.

David M. Mott has been named CEO of MedImmune (Gaithersburg, MD), effective at the end of the year. He will replace founder Wayne T. Hockmeyer, who will remain as chairman. Mr. Mott has served as vice chairman and CFO since 1998.

LION Bioscience AG (Heidelberg, Germany) has announced the appointment of Jan Mous to the position of chief scientific officer. Dr. Mous was most recently at F. Hoffmann–La Roche, where he served as



the global head of genomics technology.

George B. Rathmann and Edward E. Penhoet have been appointed to the board of directors of ZymoGenetics (Seattle, WA). Dr. Rathmann, previously the founder, CEO, and chairman of Amgen and subsequently ICOS, is the current president and CEO of Hyseq. Dr. Penhoet, founder and former president and CEO of Chiron, is currently dean of the School of Public Health at the University of California, Berkeley.

Sequenom (San Diego, CA) has announced the appointment of **Toni Schuh** as president and CEO, and his election to the board of directors. Dr. Schuh joined the company in 1996 as managing director of its German operations, and in 1998 was appointed corporate executive vice president of business development. He replaces **Hubert Koster**, who has resigned to pursue other interests, but who will become vice chairman of the board. Additionally, CSO **Charles Cantor** has been elected to the board of directors.

LifeCell (Branchburg, NJ) has announced the appointment of Steven T. Sobieski as CFO. Previously vice president, finance and treasurer of Osteotech (Eatontown, NJ), Mr. Sobieski replaces Fenel Eloi, who resigned for personal reasons.

Al Spada has been named to the recently created position of vice president of pharmaceutical development at Idun Pharmaceuticals (La Jolla, CA). Dr. Spada joins Idun from Aventis Pharmaceuticals, where he was department director of medicinal chemistry. Prior to his appointment at Aventis, he spent 10 years at Rhône-Poulenc Rorer and five years at Rorer Pharmaceuticals.

Celera Genomics (Rockville, MD) has announced that Gerald A. Steiner has joined the company as senior vice president and general manager, genomics services. Mr. Steiner comes to Celera from Monsanto, where he most recently served as general manager of its European and African agricultural businesses.

Susan J. Ward has been appointed to the newly created position of senior vice president, strategy leadership at Millennium Pharmaceuticals (Cambridge, MA). She was most recently vice president, project management at Wyeth-Ayerst Research, the principal pharmaceutical R&D division of American Home Products.

DNA Sciences (Mountain View, CA), formerly known as Kiva Genetics, has announced the appointment of **James Watson** to its board of directors. Dr. Watson was a co-recipient of the Nobel Prize in Medicine in 1962, and director of the Human Genome Project from 1988 to 1992.